News Advance
Lead authors
Mehmet Toner, PhD, director of the MGH BioMEMS Resource
Center
 Dr.
Mehmet Toner is director of the BioMicroElectroMechanical Systems
(BioMEMS) Resource Center at the MGH; professor of Surgery and Biomedical
Engineering at the Harvard Medical School; professor of Health Sciences
and Technology at Harvard-Massachusetts Institute of Technology,
Division of Health Sciences and Technology; and is a member of the
Senior Scientific Staff at the Shriners Hospital for Children. Dr.
Toner also serves as co-director of the Center for Engineering in
Medicine at Harvard Teaching Hospitals and director of the Biomedical
Engineering Research and Education Program for physicians at Harvard
Teaching Hospitals.
Dr. Toner has served on many national and international panels
and review boards, including National Institutes of Health (NIH)
Study Sections, National Science Foundation (NSF) CAREER Award panels,
NSF Nanoscience panel, NIH Nanotechnology and Tissue Engineering
panel, NIH Reparative Medicine Bioengineering Consortium, and several
DARPA strategic planning panels. Additionally, he serves on the
editorial board of several scientific journals. In 1994, he was
recognized by the YC Fung Faculty Award in Bioengineering from the
American Society of Mechanical Engineers (ASME). In 1995, he received
the Whitaker Foundation Special Opportunity Award. In 1997, he won
the John F and Virginia B Taplin Faculty Fellow Award given by Harvard
and MIT. In 1998, Dr Toner was selected to become a Fellow of the
American Institute of Medical and Biological Engineering.
Daniel Haber, MD, director of the MGH Cancer Center
 Dr.
Daniel Haber is director of the MGH Cancer Center and the Laurel
Schwartz Professor of Oncology at Harvard Medical School. His laboratory
interests have focused on the area of cancer genetics, including
the etiology of the pediatric kidney cancer Wilms tumor and genetic
predisposition to breast cancer. Most recently, his laboratory has
reported that lung cancers with activating mutations in the epidermal
growth factor receptor (EGFR) are uniquely sensitive to tyrosine
kinase inhibitors that target this receptor. This observation has
had important implications for the genotype-directed treatment of
non-small cell lung cancer, and more broadly for strategies to identify
critical genetic lesions in cancers that may serve as an "Achilles
heel" and be suitable for molecular targeting.
In addition to his research and administrative responsibilities,
Dr. Haber serves on the editorial boards of Cell and Cancer Cell,
and is a member of the American Association of Physicians (AAP),
a Doris Duke Distinguished Clinical Scholar, and Fellow of the National
Foundation for Cancer Research. He was recently awarded the Emil
Freireich Award and the AACR-Rosenthal Award for Translational Research,
and elected to the Board of Directors of the American Association
for Cancer Research (AACR).
Ronald Tompkins, MD, ScD, chief of the MGH
Burns Unit
Dr. Ronald G. Tompkins is the John Francis Burke Professor of Surgery at the Harvard Medical School, the Chief of the Burns Service of the Massachusetts General Hospital, and the Chief of Staff of the Shriners Hospitals for Children-Boston. He received a B.S. degree in Chemistry from Tulane University, an M.D. degree from Tulane Medical School, and a Sc.D. degree in medical and chemical engineering from the Massachusetts Institute of Technology. Dr. Tompkins has served on numerous national and international committees and received multiple honors including a fellowship from the American Institute for Medical and Biological Engineering and an honorary M.A. from Harvard University, and he is a senior director of the American Board of Surgery. Dr. Tompkins is recognized as an international leader in burns and trauma, and serves as the principal investigator of several National Institutes of Health grants, including U54, P50, and T32 programs. He has published more than 256 contributions to the medical literature. His research interests include the metabolic and inflammatory responses to injury and tissue engineering.
More Cancer Research »
|
